Review



receptor tki anlotinib  (MultiTarget Pharmaceuticals)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    MultiTarget Pharmaceuticals receptor tki anlotinib
    Receptor Tki Anlotinib, supplied by MultiTarget Pharmaceuticals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/receptor+tki+anlotinib/anlotinib/pm34373220-129-5-2
    Average 90 stars, based on 1 article reviews
    receptor tki anlotinib - by Bioz Stars, 2026-10
    90/100 stars

    Images

    Related Articles

    In Vitro:

    Article Title: Suppressed mitochondrial respiration via NOX5-mediated redox imbalance contributes to the antitumor activity of anlotinib in oral squamous cell carcinoma.
    Article Snippet: As a multitarget receptor TKI, anlotinib exhibits both antitumor and antiangiogenic activities and has been indicated to exert anticancer effects in vitro and in vivo (Xie et al., 2018; Lu et al., 2019; Gao et al., 2020; Song et al., 2020; Yang et al., 2020a, 2020b).

    In Vivo:

    Article Title: Suppressed mitochondrial respiration via NOX5-mediated redox imbalance contributes to the antitumor activity of anlotinib in oral squamous cell carcinoma.
    Article Snippet: As a multitarget receptor TKI, anlotinib exhibits both antitumor and antiangiogenic activities and has been indicated to exert anticancer effects in vitro and in vivo (Xie et al., 2018; Lu et al., 2019; Gao et al., 2020; Song et al., 2020; Yang et al., 2020a, 2020b).

    Colony Assay:

    Article Title: Suppressed mitochondrial respiration via NOX5-mediated redox imbalance contributes to the antitumor activity of anlotinib in oral squamous cell carcinoma.
    Article Snippet: As a multitarget receptor TKI, anlotinib exhibits both antitumor and antiangiogenic activities and has been indicated to exert anticancer effects in vitro and in vivo (Xie et al., 2018; Lu et al., 2019; Gao et al., 2020; Song et al., 2020; Yang et al., 2020a, 2020b).

    CCK-8 Assay:

    Article Title: Suppressed mitochondrial respiration via NOX5-mediated redox imbalance contributes to the antitumor activity of anlotinib in oral squamous cell carcinoma.
    Article Snippet: As a multitarget receptor TKI, anlotinib exhibits both antitumor and antiangiogenic activities and has been indicated to exert anticancer effects in vitro and in vivo (Xie et al., 2018; Lu et al., 2019; Gao et al., 2020; Song et al., 2020; Yang et al., 2020a, 2020b).

    Control:

    Article Title: Suppressed mitochondrial respiration via NOX5-mediated redox imbalance contributes to the antitumor activity of anlotinib in oral squamous cell carcinoma.
    Article Snippet: As a multitarget receptor TKI, anlotinib exhibits both antitumor and antiangiogenic activities and has been indicated to exert anticancer effects in vitro and in vivo (Xie et al., 2018; Lu et al., 2019; Gao et al., 2020; Song et al., 2020; Yang et al., 2020a, 2020b).

    Isolation:

    Article Title: Suppressed mitochondrial respiration via NOX5-mediated redox imbalance contributes to the antitumor activity of anlotinib in oral squamous cell carcinoma.
    Article Snippet: As a multitarget receptor TKI, anlotinib exhibits both antitumor and antiangiogenic activities and has been indicated to exert anticancer effects in vitro and in vivo (Xie et al., 2018; Lu et al., 2019; Gao et al., 2020; Song et al., 2020; Yang et al., 2020a, 2020b).

    Purification:

    Article Title: Suppressed mitochondrial respiration via NOX5-mediated redox imbalance contributes to the antitumor activity of anlotinib in oral squamous cell carcinoma.
    Article Snippet: As a multitarget receptor TKI, anlotinib exhibits both antitumor and antiangiogenic activities and has been indicated to exert anticancer effects in vitro and in vivo (Xie et al., 2018; Lu et al., 2019; Gao et al., 2020; Song et al., 2020; Yang et al., 2020a, 2020b).

    Sequencing:

    Article Title: Suppressed mitochondrial respiration via NOX5-mediated redox imbalance contributes to the antitumor activity of anlotinib in oral squamous cell carcinoma.
    Article Snippet: As a multitarget receptor TKI, anlotinib exhibits both antitumor and antiangiogenic activities and has been indicated to exert anticancer effects in vitro and in vivo (Xie et al., 2018; Lu et al., 2019; Gao et al., 2020; Song et al., 2020; Yang et al., 2020a, 2020b).

    Incubation:

    Article Title: Suppressed mitochondrial respiration via NOX5-mediated redox imbalance contributes to the antitumor activity of anlotinib in oral squamous cell carcinoma.
    Article Snippet: As a multitarget receptor TKI, anlotinib exhibits both antitumor and antiangiogenic activities and has been indicated to exert anticancer effects in vitro and in vivo (Xie et al., 2018; Lu et al., 2019; Gao et al., 2020; Song et al., 2020; Yang et al., 2020a, 2020b).

    Cell Culture:

    Article Title: Suppressed mitochondrial respiration via NOX5-mediated redox imbalance contributes to the antitumor activity of anlotinib in oral squamous cell carcinoma.
    Article Snippet: As a multitarget receptor TKI, anlotinib exhibits both antitumor and antiangiogenic activities and has been indicated to exert anticancer effects in vitro and in vivo (Xie et al., 2018; Lu et al., 2019; Gao et al., 2020; Song et al., 2020; Yang et al., 2020a, 2020b).

    Activity Assay:

    Article Title: Suppressed mitochondrial respiration via NOX5-mediated redox imbalance contributes to the antitumor activity of anlotinib in oral squamous cell carcinoma.
    Article Snippet: As a multitarget receptor TKI, anlotinib exhibits both antitumor and antiangiogenic activities and has been indicated to exert anticancer effects in vitro and in vivo (Xie et al., 2018; Lu et al., 2019; Gao et al., 2020; Song et al., 2020; Yang et al., 2020a, 2020b).



    Similar Products

    receptor tki anlotinib  (MultiTarget Pharmaceuticals)
    90
    MultiTarget Pharmaceuticals receptor tki anlotinib
    Receptor Tki Anlotinib, supplied by MultiTarget Pharmaceuticals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/receptor+tki+anlotinib/anlotinib/pm34373220-129-5-2
    Average 90 stars, based on 1 article reviews
    receptor tki anlotinib - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier

    Image Search Results